WebMar 1, 2011 · Background: Cisplatin-based chemotherapy is standard first-line treatment for patients (pts) with metastatic urothelial carcinoma (UC). However, a large proportion of pts with UC are considered “unfit” for cisplatin, leading to clinical trials designed specifically for cisplatin-ineligible pts, with substantial variability in eligibility criteria. WebSupplies of cisplatin , used to treat metastatic ovarian and bladder cancer, have been tight since March 6, per ASHP. The fluorouracil shortage was first reported on March 14, according to...
PD1/PDL1 inhibitors for the treatment of advanced urothelial …
WebSep 18, 2024 · Combination platinum-based chemotherapy is the standard of care for first-line treatment of advanced urothelial carcinoma in patients who are suitable candidates … WebCan’t have cisplatin chemotherapy, and their cancer is growing after 1 or more other treatments. Have cancer that is growing after treatment with immunotherapy and … thelem coulommiers
Chemotherapy for Bladder Cancer
WebDec 9, 2024 · Answer: Cisplatin-based chemotherapy has conventionally been the first-line (1L) treatment for patients with locally advanced and metastatic urothelial cancer (mUC) of the bladder. This treatment has resulted in overall survival (OS) benefit, with median OS of 13 to 15 months and approximately 15% long-term responses. WebCisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy Bladder cancer (BC) is a disease arising from the malignant cells of the urinary bladder. Myeloid-derived suppressor cells (MDSCs) expand broadly and have strong immunosuppressive activities in the cancer … WebApr 10, 2024 · The FDA’s new approval greatly expands the number of people with bladder cancer who could benefit from the drug. Doctors can now use enfortumab vedotin as a … thelem compte